Future Outlook
For Your Patients, An Unmet Need Remains For An FDA-Approved Agent1,2

Treating R/R PCNSL Remains a Major Area of Unmet Clinical Need2

  • Currently, there is no accepted standard of care in R/R PCNSL3,4
  • A fundamental challenge for R/R PCNSL research is to effectively prolong durable response while minimizing toxicity2,5-7
    • This is particularly important for elderly patients, who face poor prognosis and difficulty tolerating many treatments

What Stands in the Way of Making Progress in R/R PCNSL?

  • Lack of prospective, multicenter studies1,2,4,8
  • Low number of eligible patients1,2,4,8
  • No standard of care1,2
  • Understanding of PCNSL pathobiology is not well established1,2,4,8

Ono is rising to the challenge

pcnsl brochure

Download our brochure below to learn more and share this R/R PCNSL knowledge with your peers.

Download Brochure

*May include targeted agents, immunomodulatory agents, or other monotherapy/combination regimens.

†Also a type of chemotherapy.

Not all drugs within the presented classes are used in the treatment of R/R PCNSL.

ASCT=autologous stem cell transplant; BTKi=Bruton tyrosine kinase inhibitor; FDA=Food and Drug Administration; IMiD=immunomodulatory drug; mAbs=monoclonal antibodies; R/R PCNSL=relapsing or refractory primary central nervous system lymphoma; WBRT=whole brain radiation therapy.

References: 1. Tao K, Wang X, Tian X. Relapsed primary central nervous system lymphoma: Current Advances. Front Oncol. 2021;11;649789. doi.10.3389/fonc.2021.649789 2. Ambady P, Doolittle ND, Fox CP. Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice. Ann Lymphoma. 2021;5:23. doi:10.21037/aol-21-20 3. Mendez JS, Grommes C. Treatment of primary central nervous system lymphoma: from chemotherapy to small molecules. Am Soc Clin Oncol Educ Book. 2018;38:604-615. doi:10.1200/EDBK_200829 4. Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18(9):1297-1303. doi:10.1093/neuonc/now033 5. Liu Y, Yao Q, Zhang F. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (review). Int J Oncol. 2021;58(3):371-387. doi:10.3892/ijo.2021.5180 6. Seidel S, Kowalski T, Nilius-Eliliwi V, Schroers R, Schlegel U. Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis. Neurol Res Pract. 2023;5(1). doi:10.1186/s42466-023-00234-y 12 7. Schlegel U. Primary CNS lymphoma. Ther Adv Neurol Disord. 2009;2(2):93-104. doi:10.1177/1756285608101222 8. Lv C, Wang J, Zhou M, Xu J-Y, Chen B, Wan Y. Primary central nervous system lymphoma in the United States, 1975–2017. Ther Adv Hematol. 2022;13:20406207211066166. doi:10.1177/20406207211066166